Roth Capital Downgrades Vical (VICL) to Neutral

Roth Capital downgraded Vical (NASDAQ: VICL) from Buy to Neutral with a price target of $1.65 (from $4.65).

Analyst Debjit Chattopadhyay commented, "Phase I/II study in patients with HSV-2 raised more fundamental questions about the platform technology including: Delivery and the combination of adjuvant and antigens. The next value creating event would be the readout from its ongoing CMV vaccine in SOT in collaboration with Astellas Pharma, which is not expected until 2H16. Given the abject failure of the HSV-2 vaccine and the lack of near-term catalyst, we are moving to the sidelines and lowering target to $1.65."

For an analyst ratings summary and ratings history on Vical click here. For more ratings news on Vical click here.

Shares of Vical closed at $1.42 yesterday.

You May Also Be Interested In

• Keurig Dr Pepper (KDP) PT Raised to $39 at Jefferies
• First Cash Financial (FCFS) PT Lowered to $140 at TD Cowen
• Macquarie Upgrades ASM Pacific Technology (522:HK) (ASMVY) to Outperform